Earnings release · MRK
Merck & Co., Inc. · Filed · SEC Form 8-K, Item 2.02
EPS was -$0.54. The company issued new guidance, which gives a first marker for expectations in the periods ahead.
Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.
-$0.54
…/ earnings per share (EPS) assuming dilution was a loss per share of $0.54 and non-GAAP loss per share was $0.13.…
Guidance issued
…Full-Year 2026 Financial Outlook - Narrows and Raises Expected Worldwide Sales Range To Be Between $66.3 Billion and $67.3 Billion - Now Expects Non-GAAP EPS To Be Between $2.66 and $2.76; Outlook…
Merck's Q3 revenue rose 5%, but about $550M of U.S. purchase timing made up roughly two-thirds of the increase, and Keytruda is 47% of sales.
Forensic equity research on US stocks. No spam, unsubscribe anytime.
